These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 24393616)
21. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721 [TBL] [Abstract][Full Text] [Related]
22. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600 [TBL] [Abstract][Full Text] [Related]
24. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B; Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287 [TBL] [Abstract][Full Text] [Related]
26. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298 [TBL] [Abstract][Full Text] [Related]
27. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870 [TBL] [Abstract][Full Text] [Related]
28. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
29. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Gao S; Barber B; Schabert V; Ferrufino C Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis. Wu Y; Huang S; Wei Y; Huang M; Li C; Liang W; Qin T Front Immunol; 2024; 15():1420214. PubMed ID: 39247184 [TBL] [Abstract][Full Text] [Related]
31. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091 [TBL] [Abstract][Full Text] [Related]
32. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. von Minckwitz G; Loibl S; Maisch A; Untch M Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282 [TBL] [Abstract][Full Text] [Related]
33. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y J BUON; 2013; 18(1):57-63. PubMed ID: 23613389 [TBL] [Abstract][Full Text] [Related]
35. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409 [TBL] [Abstract][Full Text] [Related]
36. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292 [TBL] [Abstract][Full Text] [Related]
37. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940 [TBL] [Abstract][Full Text] [Related]
38. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study. Guiu S; Arnould L; Bonnetain F; Dalban C; Favier L; Desmoulins I; Créhange G; Coutant C; Fumoleau P; Coudert B Breast; 2013 Jun; 22(3):301-8. PubMed ID: 22863283 [TBL] [Abstract][Full Text] [Related]
39. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Matsubara N; Mukai H; Fujii S; Wada N Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081 [TBL] [Abstract][Full Text] [Related]
40. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]